Team:
ao.Univ.Prof.Dr.med. Martin Burian
ao.Univ.Prof.Dr.med. Dietmar Thurnher
ao.Univ.Prof.Dr.med. Michael Formanek
Ass.Prof.Dr.med. Martin Steurer
Dr.med. Barbara Zeitlinger
Dr.med. Matthias Leonhard
Ausgewählte Publikationen:
Kornfehl J, Gstoettner W, Kontrus W, Sedivy A
Transpalatine excision of a cavernous hemangioma of the infratemporal fossa.
Eur Arch Otorhinolaryngol 253;172-175. 1996
Impact factor: 0,646
Gstoettner W, Hamzavi J, Aloy A, Kornfehl J
Die funktionserhaltende chirurgische Therapie von Kopf – Hals – Tumoren mit dem CO2 Laser
Der Radiologe 38:106-108, 1998
Impact factor: 0,621
Gstoettner W, Matula C, Hamzavi J, Kornfehl J, Czerny Ch, Temmel A, Güler N, Novak K
Long term results of different treatment modalities in 37 patients with glomus jugulare tumors
Europ Arch Otorhinolaryngol 256:351-5, 1999
Impact factor: 0,646
Anton J V, Gstoettner W, Matula Ch
Interdisziplinäres Management bei der Behandlung von Tumoren der vorderen Schädelgrube
Wien Klin Wochenschr 2;112:473-6, 1999
Impact factor: 0,646
Muhm M, Polterauer P, Gstoettner W, Temmel A, et al.
Glomus caroticum – Chemodectom. Übersicht über die aktuelle Diagnostik und Therapie.
Wien Klin Wochenschr 112:115-120, 2000
Impact factor: 0,646
Anton J V, Schultze J, Gstoettner W, Matula Ch
Tumors of the anteriorskull base. Effects of perioperative imaging on adjuvant radiotherapy planning
Roentgenpraxis 53(1):10-5, 2000
Kierner AC, Zelenka I, Gstoettner W
The sternocleidomastoid flap: its indications and limitations.
Laryngoscope 111:2201-4, 2001
Impact factor: 1,457
Saringer W, Kitz K, Czerny C, Kornfehl J, Gstoettner W, Matula C, Knosp E
Paragangliomas of the Temporal Bone: Results of Different Treatment Modalities in 53 Patients
Acta Neurochir 144: 1255-1264, 2002
Impact factor: 0,957
Vogl TJ, Schick C, Mack M, Gstoettner W
Diagnostic imaging and differential diagnosis of pathological processes of the sinus cavernosus
Radiologe 43(2) 161-70, 2003
Impact factor: 0,621
Knecht R, Peters S, Adunka O, Strebhardt K, Gstoettner W, Hambek M
Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Anticancer Res 23:2577-83, 2003
Impact factor: 1,416
Knecht R, Peters S, Hambek M, Solbach C, Baghi M, Gstoettner W
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Anticancer Res 23:4789-96, 2003
Impact factor: 1,416
Hambek M, Baghi M, Strebhard K, May A, Adunka O, Gstoettner W, Knecht R
STAT 3 activation in head and neck squamous cell carcinomas is controlled by the EGFR
Anticancer Res 24:3881-6. 2004
Impact factor: 1,416
Peters S, Hambek M, Gstoettner W, Knecht R
Wertigkeit von Tissue-Microarrays in Immunhistochemischen proliferationsassoiziierten Reihenuntersuchungen von Kopf-Hals-Karzinomen
HNO 2004 52:409-412, 2004
Impact factor: 0,722
Adunka O, Unkelbach M C, Gstoettner W, Hambek M, Knecht R
Ein klinisch-wissenschaftliches Datenbanksystem zur Erfassung und Auswertung onkologischer Daten im Kopf-Halsbereich
HNO, 53(1) 39-45, 2005
Impact factor: 0,722
Knecht R, Peters S, Hambek M, Solbach C, Baghi M, Gstoettner W
EGFR-antibody-supplemented TPF chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment.
Adv Otorhinolaryngol 62:81-91, 2005
Hambek M, Baghi M, Baumann H, Strebhard K, Adunka O, Gstoettner W, Knecht R
Iressa (ZD 1839) inhibits phosphorylation of three different downstream signal transducers in head and neck cancer (SCCHN)
Anticancer Res (3B):1871-5, 2005
Impact factor: 1,416
Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstoettner W, Knecht R
The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers
Anticancer Res 25(5):3665-70, 2005
Impact factor: 1,416
Hambek M, Baghi M, Strebhard K, Baumann H, Gstoettner W, Knecht R
Reduction of cisplatin dosage by ZD 1839
Anticancer Res. 25(6B):3985-8, 2005
Impact factor: 1,416
Baghi M, Hambek M, May A, Radeloff A, Gstoettner W, Knecht R
Adjuvant Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Anticancer Res. 26:559-564, 2006
Impact factor: 1,416
Baghi M., Hambek M, Wagenblast J, May A, Gstoettner W, Knecht R
A Phase II Trial of Docetaxel, Cisplatin and 5-Fluorouracil in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Anticancer Res. 26:585-590, 2006
Impact factor: 1,416
Hambek M, Adunka O, Baghi M, Gstoettner W, Knecht R
AdOnco: A Database for Clinical and Scientific Documentation of Head and Neck Oncology
Annals of Otology, Rhinology & Laryngology 115(2):144-149, 2006
Impact factor:0,954
Czerny C, Nemec M, Krestan C, Gstoettner W
Benign and malignant lesions in the region of the inner ear and cerebellopontine angle
Radiologe.Mar;46(3):197-204, 2006
Impact factor:0,621
Hambek M, Werner C, Baghi M, Gstoettner W, Knecht R
Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy
Anticancer Res Mar-Apr;26(2A):1091-5, 2006
Impact factor: 1,416
Bisdas S, Baghi M, Abdelkader A, Gstoettner W, Fetscher S, Vogl T
Primary B-Cell Lymphoma of the Central Skull Base
Clin Neuroradiol 16:258-61, 2006
Hambek M, Werner C, Baghi M, Gstoettner W, Knecht R
Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation
Eur J Cancer 43(10)1502-7, 2007
Impact factor: 4,454
Baghi M, Mack M, Hambek M, Bisdas S, Muerthel R, Wagenblast J, Gstoettner W, Knecht R
Usefulness of MRI volumetric evaluation in patients with SCCHN treated with neoadjuvant chemotherapy
Head Neck J SCI SPEC Feb, 29(2):104-8,2007
Impact factor: 2,007
Bisdas S, Baghi M, Huebner F, Mueller C, Knecht R, Vorbucher M, Gstoettner W, Vogl T
In vivo proton MR spectroscopy of primary tumours, nodal and recurrent disease of the extracranial head and neck
Eur Radiol 17(1):251-7, 2007
Impact factor: 3,405
Baghi M, Mack M, Wagenblast J, Hambek M, Rieger J, Bisdas S, Gstoettner W, Engels K, Vogl T, Strebhardt K, Knecht R
Iron oxide particle enhanced Magnetic Resonance Imaging for detection of benign lymph nodes in head and neck, how reliable are the results?
Anticancer Reasearch 27:3571-5, 2007
Impact factor: 1,414
Baghi M, Wagenblast J, Hambek M, Radeloff A, Gstoettner W, Scherzed A, Spaenkuch B, Yuan J, Hornung S, Strebhardt K, Knecht R
Demands of the caring relatives in head and neck cancer patients.
Laryngoscope 117(4):712-6, 2007
Impact factor: 1,801
Bisdas S, Fetscher S, Feller AC, Baghi M, Knecht R, Gstoettner W, Vogl TJ, Balzer JO
Primary B cell lymphoma of the sphenoid sinus: CT and MR characteristics with correlation to perfusion and spectroscopic imaging features.
Eur. Arch ORL 264 (10):1207-13, 2007
Impact factor: 0,648
Baghi M, Wagenblast J, Hambek M, Moertel S, Gstoettner W, Spaenkuch B, Yuan J, Strebhardt K, Knecht R
Pretreatment haemoglobin level predicts remission rate and survival after TPF-induction polychemotherapy in advanced head and neck cancer patients
Clin ORL, 33:245-51, 2008
Impact factor: 1,477
Helbig M, Krysztoforski K, Kucharski J, Popek M, Kroll T, Helbig S, May A, Gstoettner W, Kozak J
Navigation-assisted sonography for soft tissues in the head and neck region.
HNO 20081011, Medline 2008
Impact factor: 0,653
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstoettner W, Ackermann H, Hambek M, May A
Craniofacial reconstruction with bone-anchored epithesis in head and neck cancer patients – a valid way back to self-perception and social reintegration
Anticancer research, 28:2349-52, 2008
Impact factor: 1,414
Wagenblast J, Baghi M, Helbig M, Arnoldner C, Bisdas S, Gstoettner W, May A, Knecht R, Hambek M
Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
Anticancer research, 28:2239-43, 2008
Impact factor: 1,414
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstoettner W, May A, Knecht R, Hambek M
Effects of combination treatment of bortezomib and dexamethasone in SCCHN cell lines depend on tumor cell specificity.
Oncol Rep 20:1207-11, 2008
Impact factor: 1.597
Helbig M, Krysztoforski K, Krowicki P, Helbig S, Gstoettner W, Kozak J
Development of prototype for navigated real-time sonography for the head and neck region
Head Neck J SCI SPEC 30:215-21, 2008
Impact factor: 2,007
Wagenblast J, Hambek M, Baghi M, Gstoettner W, Strebhardt K, Ackermann H, Knecht R
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines
Anticancer Res, 134:323-30, 2008
Impact factor: 1,414
Helbig M, Krysztoforski K, Kroll T, Kucharski J, Popek M, Helbig S, Gstoettner W, May A, Kozak J
Navigation-supported and sonographically-controlled fine-needle puncture in soft tissues of the neck.
Ultrasound Med Biol 35 (3); p. 436-42, 2009
Impact factor:1,922
Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstoettner W, Ackermann H, Hambek M, Knecht R
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
J. Cancer Res. Clin. Oncol 135(3)387-93, 2009
Impact factor: 2,366
